

## Chronic Liver Disease and the Role of Non-Invasive Diagnostic Tools: Exploring the Advancements in Elastography and Biomarkers for Assessing Fibrosis and Cirrhosis

<sup>1</sup>Dr Shakir Hussain keerio, <sup>2</sup>Dr Ikram, <sup>3</sup>Mohib Ali, <sup>4</sup>Dr Hadi Raza, <sup>5</sup>Dr. Muhammad Sohail Baig, <sup>6</sup>Dr Muhammad Javed

Submission: 14 January 2026 | Acceptance: 31 January 2026 | Publication: 22 February 2026

<sup>1</sup>Assistant professor Peoples university of medical and health sciences for women's Nawab Shah.

<sup>2</sup>University of Health Sciences (UHS), Lahore

<sup>3</sup>University of Health Sciences (UHS), Lahore

<sup>4</sup>Pakistan Institute of Medical Sciences, Islamabad

<sup>5</sup>Pakistan Institute of Medical Sciences, Islamabad

<sup>6</sup>Associate Professor Gastroenterology Department of Medicine Gajju Khan Medical College and Bacha Khan Medical Complex Shah Mansoor Swabi

### Abstract:

**Background:** Chronic liver disease (CLD) incorporate a continuum of liver pathologies that can leads to fibrosis, hepatic failure and cirrhosis. Early observation and monitoring are mainly essential because it help to reduce disease load and improve its outcomes. The background of this study is specifically related to the chronic, elastography and some biological marks which help to solve lots of problem related to patients.

**Aim:** This study pursues to evaluate the effectiveness of non-intrusive diagnostic tool. We use several types of techniques which is particularly used in elastographical techniques and serum biomarkers, in evaluation of liver fibrosis and cirrhosis.

**Methods:** A structured review of recent publications 2016-2022 was conducted, its main focus is on studies to calculate transient electrography, magnetic resonance electrography known as MRE, serum biomarkers like Fibro Test, APRI, and FIB-4 and acoustic radiation force impulse imaging.

**Results:** Elastography methods show high sensitivity and specificity in detecting significant cirrhosis and fibrosis. Biological markers provide interdependent value but with various accuracy which is based on aetiology. Combine approach the method to improve diagnostic accuracy. Accuracy and precision both depends upon the working and treatment.

**Conclusion:** Non-intrusive diagnostics, especially elastographical which is combined with serum markers which offers a reliable, safety alternatives and to liver biopsy for co-ordination of cirrhosis and liver fibrosis.

**Keywords:** morbidity, spectrum, cirrhosis, fibrosis.

### Introduction:

Chronic liver disease or CLD shows a consequential global health concern, which is contributing to the considerable value of mortality, morbidity, and economic load of worldwide [1]. The morbidity and mortality change with economical changes [2]. It embrace a specific spectrum of progressions liver disorders which includes hepatitis B virus or HBV infection [3]. Hepatitis C virus or HCV infection, alcohol based induced liver injury and non-alcoholic fatty liver disease, which is showing increased prevalence due to increasing rates of obesity, metabolic syndrome and diabetes [4]. These conditions often progress clandestinely, with is fewer or showing no symptoms in early stages [5]. Results shows that many patients are diagnosed only after the disease has been on the advancement of cirrhosis or liver failure [6], it limits the efficacy of therapeutic interfere and particularly lowers the survival rates [7]. Early diagnosis and mount of liver fibrosis are crucial for guiding the treatment's decisions, its monitoring,

disease progression, and also improving of long-term outcomes[8]. Consistently, liver biopsy has been regarded as the higher standard for the evaluation of hepatic fibrosis and inflammatory response [9]. However, its intrusive nature, increased cost and risk of complications including bleeding, and issues with sampling vitality have limited widespread of its uses and acceptance [10]. Showing response toward these limitations, there has been response to show a growing interest for developing and validation of non-intrusive diagnostic tools [11]. Advancement in imaging technologies includes transient Elastography, magnetic resonance Elastography or MRE, and ultrasound techniques on side by side [12]. The emergence of serological events and composition of scoring systems such as FIB, ELF score and APRI, have cover the way for more attainable, safe, and work on effective cost which alternates to the liver biopsy [13]. These noninterfering modalities are increasing day by day and being unified which integrates into the clinical practice which enhance disease monitoring, early detection and risk hierarchy in patients with chronic liver disease.

**Methodology:**

A structured publication reviews was conducted using databases such as PubMed, Scopus, and springer. Inclusion criteria includes original articles which is published between 2016 and 2025, which focuses on non-intrusive aspects of cirrhosis and liver fibrosis in adults. Further studies were selected which evaluate the diagnostically performance of Transient Elastography (TE), magnetic resonance Elastography or MRE, ARFI, and biological markers such as APRI, FIB-4, and Fibro-Testing. Data were concluded on the basis of sensitivity, specific setup, positive prediction and its value or PPV, and negative predictive value or NPV.

Additional values, such as area which is under the ROC curve or AUC, diagnostic odd ratios or DOR, and likewise ratio of LR+ and LR-. Both of these were also taken into specific account where availability is to strengthen the comparative analysis of specific diagnostic tools. Articles are including in both prospective and retrospectively designs, and preferences were given to peer-reviewed group, higher quality studies with whole clear methodologies and sample the sizes above 150 participants.

**Results:**

This analysis of elastography techniques were exactly demonstrate the MRE which had the highest diagnostical performance, with a high sensitivity of 85–95%, speciality of 85–95%, of an AUROC is approximately 0.94, which make it the accuracy and modality, eventually less availability which is due to higher cost. Transient Elastography or TE and also SWE, both of them showed strongest performance with AUROC around about 0.90, On the other hand, ARFI exhibited little bit lower accuracy with an AUROC of ~0.85. The SWE was also noted down to be lessly affected by obesity issue as compared to ARFI and TE.

For these biological markers, the ELF Score demonstrates the higher diagnostic accurate measure with the sensitivity of 90–95%, specifically 85–90%, and AUROC of ~0.90. Fibro Tests and NFS follow this closely with AUROC with is around about 0.86, Further, FIB-4 and APRI shows lower performances, individually in intermediate fibrosis stages, with AUROC of ~0.75 and ~0.80, respectively. Biological markers were found more easy to access and cost-effectiveness for initial screenings, whereas imaging techniques provided by the greater diagnostic value and also precise for the confirmation and effectiveness.

**Table:1 Diagnostic Accuracy of Elastography Techniques for Detecting Liver Fibrosis**

Technique	Sensitivity	Specificity	AUROC	Notes
-----------	-------------	-------------	-------	-------

Technique	Sensitivity	Specificity	AUROC	Notes
<b>Transient Elastographical technique</b>	80-95%	80-85%	~0.90	Widely used by the effect of obesity and ascites
<b>ARFI (Acoustic Radiation Force Impulse)</b>	75-80%	85-90%	~0.84	Integrated into conditional ultrasound; operator-dependents
<b>SWE (Shear Wave Elastography)</b>	80-90%	80-85%	~0.90	High dimensional resolution; less affected by obesity
<b>MRE (Magnetic Resonance Elastography)</b>	80-90%	90-95%	~0.93	Most accurate; expensive and less available

**Table:2 Diagnostic Performance of Biological markers in Prediction of Advanced Fibrosis**

Biomarker/Test	Sensitivity	Specificity	AUROC	Comments
<b>FIB-4 Index</b>	75-80%	65-70%	~0.70	Easy to calculate and widely used in primary care
<b>APRI (AST to Platelet Ratio Index)</b>	65-75%	60-75%	~0.75	Simple and inexpensive and lower accuracy for intermediate stages
<b>NAFLD Fibrosis Score (NFS)</b>	70-85%	70-85%	~0.85	Useful in NAFLD and includes BMI and glucose levels
<b>Fibro Test</b>	80-90%	75-85%	~0.85	Commercial test and includes multiple serum markers
<b>ELF Score (Enhanced Liver Fibrosis)</b>	85-95%	80-90%	~0.89	Measures ECM turnover and good for longitudinal assessment

## Discussion:

In this study, Elastography techniques are particular Magnetic Resonance Elastography or MRE [14], which demonstrate high ranking diagnostic accuracy for liver fibrosis which assess due to their high dependability and ability to sample out the entire liver function and structure[15].MRE is specifically effective to detect advancing stages of fibrosis and is less affected by complicating factors such as obesity or inflammatory response[16].However its limitations included high cost, limited availability,also includes longer scan times which restrict its wide spreading use in daily clinical settings.Transient Elastography or TE, On the other hand, remains the most widely used modality spectrum [17].Due to its portability factor, speed, and user-friendly connection [18]. TE is showing good for accuracy in detecting significant cirrhosis and fibrosis[19].This make it very suitable for point-of-care, screening, specifically in primary take care and outpatient treatments [20]. After everything, its reliability can make compromise on patients with higher index of body mass or narrow inter-costal spaces [21]. Acoustic Radiation Force Impulse Imaging or ARFI, which integrated into high power ultrasound machines, which provides an intermediate solution [22]. It gives offer related to the advantage of real-time image and allows concurrent evaluation of liver hardness and morphological event [23].ARFI diagnostic performance is compared to TE, with the additive benefits of being operative-dependent, which can be a bridge between sword in terms of consistency [24]. Biological markers include panels based on serum and its indirect markers of injury in liver, plays a supportive role in noninvasive fibrosis assessments. They are exceptionally useful

in stratifying risk of patients and guidelines related to the decisions regarding the need of random testing and liver biopsy [25]. Moreover, their accurate rate may vary which depends upon the underlying liver disease called etiology, nonalcoholic fatty liver disease such as viral hepatitis, (NAFLD), or alcohol-related liver disease, as well as patient's specific factors including age, sex, and co-existing conditions. The specific integration of Elastography with biological marker analysis has been showing to enhance diagnostic precise suggestion. This combination approach and reduce the limited effects of individuality methods and improves risk stratification, allowing for good information and clinical decisions making. It also helps to facilitates longitudinal designation of disease progression or either regression, which pay vital role for optimizing the treatment strategy and improving the outcomes of patient. Significant measures should be take to get accuracy.

## Conclusion:

The adventure of non-intrusive diagnostically tools marking as a prototype shift of managing chronic liver diseases. Elastography techniques such as specific when paired upon with serum biological markers which provide clinical rhythms with accuracy, productiveness, and safe alternatives of liver biopsy. Further advancements and standard levels of these tools will improve outcomes of patients and enable it to broader implementations in routine clinical practices. Regular clinical practices are necessary for improvement and beneficial. The evolutions of non-intrusive diagnostic tool can signifies a important shift in managing chronic type of liver diseases. Elastography techniques, temporarily when get combine with serum biological markers, it offers a comprehensively approaches to liver assessments. For this instance, it Enhanced Liver Fibrosis or ELF, all test utilizes different blood sample to measures some specific biological markers, which provides rapid results. It also reduces the need for intrusive liver biopsies . With addition of, transient elastography, such as FibroScan, some employs ultrasound waves to the assessment of liver hardness, aids in the detection and monitoring level of liver fibrosis without the discomfort associated with traditional biopsy procedures. AI models, with trained extensive imaging of data, can also now classify fibrosis stages on higher sensitivity, even in several setting with lacking experienced several radiologists. For example, deep convolution all neural networks or DCNN have demonstrated overall average sensitivity of 0.86 for identifying liver fibrosis stages . When combined with elastographical measurements, these AI models offer improved diagnostic precisions with accuracy. It facilitates early detections and personalized the treatment strategies. However, the integrational series of serum biological markers such as Pro-C3 or miRNAs which have strong link with diagnostic panels which has shown different promise in stratifying several patients based upon fibrosis risk. These biological markers, which is associated with fibrogenesis, provide extra layers of information, who enables clinicians to check out interventions more effectively and accurately .

## Reference:

1. Maino, C., Vernccio, F., Cannella, R., Cristoferi, L., Franco, P. N., Carbone, M., ... & Ippolito, D. (2024). Non-invasive imaging biomarkers in chronic liver disease. *European Journal of Radiology*, 111749.
2. Biris, A. I., Karamatzanis, I., Biri, D., Biris, I. A., Maravegias, N., & Maravegias Sr, N. (2024). Non-Invasive Ultrasound Diagnostic Techniques for Steatotic Liver Disease and Focal Liver Lesions: 2D, Colour Doppler, 3D, Two-Dimensional Shear Wave Elastography (2D-SWE), and Ultrasound-Guided Attenuation Parameter (UGAP). *Cureus*, 16(10).
3. Pozowski, P., Bilski, M., Bedrylo, M., Sitny, P., & Zaleska-Dorobisz, U. (2025). Modern ultrasound techniques for diagnosing liver steatosis and fibrosis: A systematic review with a focus on biopsy comparison. *World Journal of Hepatology*, 17(2), 100033.
4. Scarlata, G. G. M., Ismaiel, A., Gambardella, M. L., Leucuta, D. C., Luzzza, F., Dumitrascu, D. L.,

- & Abenavoli, L. (2024). Use of non-invasive biomarkers and clinical scores to predict the complications of liver cirrhosis: a bicentric experience. *Medicina*, 60(11), 1854.
5. Garg, S., Varghese, M., Shaik, F., Jatin, F. N. U., Sachdeva, D., Eranhikkal, F. W., ... & Eranhikkal Jr, F. W. (2025). Efficacy of Non-invasive Biomarkers in Diagnosing Non-alcoholic Fatty Liver Disease (NAFLD) and Predicting Disease Progression: A Systematic Review. *Cureus*, 17(2).
  6. Hudson, D., Afzaal, T., Bualbanat, H., AlRamdan, R., Howarth, N., Parthasarathy, P., ... & Arab, J. P. (2024). Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: the progressive shift from liver biopsy to noninvasive techniques. *Therapeutic Advances in Gastroenterology*, 17, 17562848241276334.
  7. Carnazzo, V., Pignalosa, S., Tagliaferro, M., Gragnani, L., Zignego, A. L., Racco, C., ... & Basile, U. (2025). Exploratory study of extracellular matrix biomarkers for non-invasive liver fibrosis staging: A machine learning approach with XGBoost and explainable AI. *Clinical Biochemistry*, 135, 110861.
  8. Addissouky, T. A., El Sayed, I. E. T., Ali, M. M., & Alubiady, M. H. S. (2024). Optical insights into fibrotic livers: Applications of near-infrared spectroscopy and machine learning. *Archives of Gastroenterology Research*, 5(1), 1-10.
  9. Sun, Y., Hu, D., Yu, M., Liang, S. B., Zheng, Y., Wang, X., & Tong, G. (2025). Diagnostic Accuracy of Non-Invasive Diagnostic Tests for Nonalcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. *Clinical Epidemiology*, 53-71.
  10. Bourganou, M. V., Chondrogianni, M. E., Kyrou, I., Flessa, C. M., Chatzigeorgiou, A., Oikonomou, E., ... & Kassi, E. (2025). Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies. *International Journal of Molecular Sciences*, 26(4), 1589.
  11. Hernandez, R., Garcia-Rodriguez, N. S., Arriaga, M. A., Perez, R., Bala, A. A., Leandro, A. C., ... & Galan, J. A. (2025). The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologies. *Frontiers in Medicine*, 12, 1513598.
  12. Delfan, N., Moghadam, P. K., Khoshnevisan, M., Chagahi, M. H., Hatami, B., Asgharzadeh, M., ... & Dehnad, K. (2024). AI-Driven Non-Invasive Detection and Staging of Steatosis in Fatty Liver Disease Using a Novel Cascade Model and Information Fusion Techniques. *arXiv preprint arXiv:2412.04884*.
  13. Tudor, M. S., Gheorman, V., Simeanu, G. M., Dobrinescu, A., Pădureanu, V., Dinescu, V. C., & Fortofoiu, M. C. (2024). Evolutive Models, Algorithms and Predictive Parameters for the Progression of Hepatic Steatosis. *Metabolites*, 14(4), 198.
  14. Basil, B., Myke-Mbata, B. K., Eze, O. E., & Akubue, A. U. (2024). From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome—current insights and future directions. *Clinical diabetes and endocrinology*, 10(1), 39.
  15. Zhang, L. X., Burgio, M. D., Vilgrain, V., Fang, C., Sidhu, P. S., Cloutier, G., & Tang, A. (2024). Quantitative Ultrasound and Ultrasound-Based Elastography for Chronic Liver Disease: Practical Guidance, From the AJR Special Series on Quantitative Imaging. *American Journal of Roentgenology*.
  16. Khan, N., Khan, A., Naseer, S., Umar, Z., Abbas, S., Ahmad, F., ... & Bashir, A. (2025). Non-Alcoholic Fatty Liver Disease and Its Progression: Impact of Metabolic Syndrome and Future Treatment Strategies. *Indus Journal of Bioscience Research*, 3(3), 146-152.
  17. Sotoudehian, M. J. (2025). Value of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Review of its Serum Biomarker Role. *Current protein & peptide science*, 26(1), 6-21.
  18. Martí-Aguado, D., & Martí-Bonmatí, L. (2025). Magnetic Resonance Imaging Quantification of Steatosis, Iron, and Fibrosis in Chronic Liver Disease. In *Experimental and Clinical Methods in Hepatic Encephalopathy Research* (pp. 39-59). New York, NY: Springer US.

19. Dionisi, T., Galasso, L., Antuofermo, L., Mancarella, F. A., Esposto, G., Mignini, I., ... & Zocco, M. A. (2024). Shear Wave Dispersion Elastography in ALD and MASLD: Comparative Pathophysiology and Clinical Potential—A Narrative Review. *Journal of Clinical Medicine*, 13(24), 7799.
  20. Elhoseeny, M. M., Abdulaziz, B. A., Mohamed, M. A., Elsharaby, R. M., Rashad, G. M., & Othman, A. A. (2024). Fetuin-A: a relevant novel serum biomarker for non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective case-control study. *BMC gastroenterology*, 24(1), 226.
  21. Yang, F., Hu, M., Zhang, H., Zheng, X., Chen, L., Zhu, L., & Zhang, L. (2024). Protocol for a Longitudinal Cohort Study to understand characteristics and risk factors underlying vibration-controlled transient elastography-diagnosed metabolic dysfunction-Associated fatty liver Disease Children. *Diabetes, Metabolic Syndrome and Obesity*, 4627-4639.
  22. Vengateswaran, H. T., Habeeb, M., You, H. W., Aher, K. B., Bhavar, G. B., & Asane, G. S. (2024). Hepatocellular carcinoma imaging: Exploring traditional techniques and emerging innovations for early intervention. *Medicine in Novel Technology and Devices*, 100327.
  23. Vengateswaran, H. T., Habeeb, M., You, H. W., Aher, K. B., Bhavar, G. B., & Asane, G. S. (2024). Hepatocellular carcinoma imaging: Exploring traditional techniques and emerging innovations for early intervention. *Medicine in Novel Technology and Devices*, 100327.
  24. Huang, L., Luo, Y., Zhang, L., Wu, M., & Hu, L. (2025). Machine learning-based disease risk stratification and prediction of metabolic dysfunction-associated fatty liver disease using vibration-controlled transient elastography: Result from NHANES 2021–2023. *BMC gastroenterology*, 25(1), 255.
- Ntikoudi, A., Papachristou, A., Tsalkitzi, A., Margari, N., Evangelou, E., & Vlachou, E. (2025). Metabolic-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes: Mechanisms, Diagnostic Approaches, and Therapeutic Interventions. *Diabetology*, 6(4), 23.